reports
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Cli...
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination The combination of denifanstat and resmetirom was generally well-toleratedPharmacokinetic (PK) results support further development of the combinationA Phase 2 trial of a denifanstat/resmetirom combination in F4 MASH patients is planned to initiate in 2H 2026 SAN MATEO, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrot...
- Yun Zhong
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ACRS ACLARIS THERAPEUTICS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
KNSA KINIKSA PHARMACEUTICALS
ORIC ORIC PHARMACEUTICALS
VRDN VIRIDIAN THERAPEUTICS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
GLUE MONTE ROSA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
CMPX COMPASS THERAPEUTICS
MLTX MOONLAKE IMMUNOTHERAPEUTICS
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
ARTV ARTIVA BIOTHERAPEUTICS INC
SGMT SAGIMET BIOSCIENCES INC
ORKA ORUKA THERAPEUTICS INC
BBOT BRIDGEBIO ONCOLOGY THERAPEUTICS INC
- Yun Zhong
Sagimet Biosciences and TAPI Announce Global License Agreement for Inn...
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program License Agreement grants Sagimet a global, exclusive license to innovative forms of resmetirom active pharmaceutical ingredient (API) developed by TAPI and covered by TAPI patent applicationsCollaboration supports Sagimet’s fixed-dose combination (FDC) program currently in clinical developmentSagimet’s Phase 1 pharmacokinetic (PK) trial of combination of denifanstat and resmetirom is underway with topline data anticipated by the end of 2025Sagime...
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Ap...
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration SAN MATEO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis Pharma Inc. issued a December 10 statement that China’s National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) ...
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing R...
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN MATEO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that, in connection with the hiring of three employees, the Compensation Committee of Sagimet’s Board of Directors approved inducement grants of 42,800 stock options in aggregate to purchase shares of the Company’s Series A common stock as determined based on the Black ...
Paycom Software Inc: 1 director
A director at Paycom Software Inc sold 2,192 shares at 165.849USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MSBI MIDLAND STATES BANCORP
WMG WARNER MUSIC GROUP CORP.
IIIV I3 VERTICALS
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
SPT SPROUT SOCIAL
BMEA INC.
PBBK BIOMEA FUSION
NRDY INC.
MAIA PB BANKSHARES
SMRT INC.
SPRU NERDY INC.
BAER MAIA BIOTECHNOLOGY INC
SGI SMARTRENT INC
GF SPRUCE POWER HOLDING CORP
AFCG WILDFIRE NEW PUBCO
KITT INC.
SOMNIGROUP INTERNATIONAL INC.
THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TPC TUTOR PERINI CORPORATION
RPD RAPID7 INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
GLP GLOBAL PARTNERS LP
DIN DINE BRANDS GLOBAL INC.
RIGN TRANSOCEAN LTD.
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
IIPR INNOVATIVE INDUSTRIAL PROPERTIES INC
MLP MAUI LAND & PINEAPPLE CO. INC.
GSHD GOOSEHEAD INSURANCE
VRCA VERRICA PHARMACEUTICALS
AEYE AUDIOEYE INC
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
UTZ UTZ BRANDS INC (A)
ABCL ABCELLERA BIOLOGICS
PBBK PB BANKSHARES
NEXT INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
ENOV EVOLV TECHNOLOGIES HLDGS INC
QDEL ENOVIS CORPORATION
J QUIDEL CORP
EBC JACOBS SOLUTIONS INC.
WEST EASTERN BANKSHARES INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
MNR GRAN TIERRA ENERGY INC.
GAM MACH NATURAL RESOURCES LP
SPRU GENERAL DE ALQUILER DE MAQUINARIA
GF SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
- Jonathan Moreland
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Heal...
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference SAN MATEO, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the 8th Annual Evercore ISI Healthcare Conference on Tuesday, December 2, 2025, in Coral Gables, Florida, with a fireside chat at 12:55pm ET (link ). A webcast of the fireside chat will be available in the Investors & Media sectio...
Texas Capital Announces the Liquidation of the Texas Small Cap Equity ...
Texas Capital Announces the Liquidation of the Texas Small Cap Equity Index ETF DALLAS, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The Board of Trustees of the Texas Capital Funds Trust (the “Board”) has authorized an orderly liquidation of the Texas Capital Texas Small Cap Equity Index ETF (NASDAQ: TXSS) (the “Fund”). After careful consideration of the Fund’s size, asset composition and growth trajectory, the Board determined that it is advisable and in the best interest of the Fund and its shareholders to liquidate the Fund. As constructed, TXSS shared some of the portfolio constituents and othe...
- Yun Zhong
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and P...
Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of its pre-NDA consultation with China’s NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris SAN MATEO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical...
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Live...
Sagimet Biosciences Presents Two Denifanstat Posters at AASLD—The Liver Meeting® 2025 A secondary analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis, inflammation and steatosis in advanced qF4 MASH patients as measured by artificial intelligence (AI) digital pathology In a second poster, spatial computational histology relying on baseline fibrosis features was used to predict response to denifanstat SAN MATEO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel thera...
Strawberry Fields REIT Announces Q4 2025 Cash Dividend of $0.16 per Co...
Strawberry Fields REIT Announces Q4 2025 Cash Dividend of $0.16 per Common Share SOUTH BEND, Ind., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) today announced that its Board of Directors declared a cash dividend on its common stock in the amount of $0.16 per share (the “Dividend”). The Dividend will be payable in cash on December 30, 2025, to stockholders of record as of the close of business on December 16, 2025. About Strawberry Fields REIT Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged...
Strawberry Fields REIT Announces Third Quarter 2025 Operating Results
Strawberry Fields REIT Announces Third Quarter 2025 Operating Results SOUTH BEND, Ind., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) (the “Company”) reported today its operating results for the quarter ended September 30, 2025. FINANCIAL HIGHLIGHTS 100% of contractual rents collected.On July 1, 2025, the Company completed the acquisition of nine skilled nursing facilities, comprised of 686 beds, located in Missouri. The acquisition was for $59,000,000 and the Company funded the acquisition utilizing working capital. Eight of the facilities were l...
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
- Jonathan Moreland
TCBI TEXAS CAPITAL BANCSHARES INC.
EVEREST RE GROUP LTD.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
FMNB FARMERS NATIONAL BANC CORP.
FFIN FIRST FINANCIAL BANKSHARES INC
FCN FTI CONSULTING INC.
CRMD CORMEDIX INC.
CNS COHEN & STEERS INC.
CINF CINCINNATI FINANCIAL CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ANGO ANGIODYNAMICS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
QRHC QUEST RESOURCE HOLDING
QTA QUATERRA RESOURCES INC.
ATRO ASTRONICS CORPORATION
NSC NORFOLK SOUTHERN CORPORATION
INBK FIRST INTERNET BANCORP
GCBC GREENE COUNTY BANCORP INC.
UTG REAVES UTILITY INCOME FUND
ITGR INTEGER HOLDINGS CORPORATION
WDFC WD-40 COMPANY
BX THE BLACKSTONE GROUP L.P.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
WGO WINNEBAGO INDUSTRIES INC.
NWFL NORWOOD FINANCIAL CORP.
OBNK ORIGIN BANCORP
CHMG CHEMUNG FINANCIAL CORP.
AVTR AVANTOR
RYES INC.
VRDN PATRIOT MINEFINDERS INC.
SMMT VIRIDIAN THERAPEUTICS INC
INTA SUMMIT THERAPEUTICS INC
NVCT INTAPP INC
EBC NUVECTIS PHARMA INC
NMRA EASTERN BANKSHARES INC
EP NEUMORA THERAPEUTICS INC
CLS EMPIRE PETROLEUM CORP
GF CELESTICA INC.
ECF THE NEW GERMANY FUND
NUGN INC.
XFOR ELLSWORTH FUND LTD
STBA LIVENTO GROUP
KITT INC.
X4 PHARMACEUTICALS INC.
S&T BANCORP
INC.
NAUTICUS ROBOTICS HOLDINGS INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.